About NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)
NovaBay Pharmaceuticals, Inc., formerly NovaCal Pharmaceuticals, Inc., is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox. Its Avenova with Neutrox removes debris from the skin on the eyelids and lashes without burning or stinging. It develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. Its Aganocide compounds, led by auriclosene (NVC-422), are synthetic molecules with activity against bacteria, viruses and fungi. The Company's dermatology product includes CelleRx, a cleansing solution for post laser resurfacing, chemical peels and other cosmetic surgery procedures. Its wound care business includes the business of NeutroPhase product.
Industry, Sector and Symbol
Industry Biotechnology & Medical Research
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-184.30%
Return on Assets-56.33%
Frequently Asked Questions for NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)
What is NovaBay Pharmaceuticals' stock symbol?
NovaBay Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NBY."
When did NovaBay Pharmaceuticals' stock split? How did NovaBay Pharmaceuticals' stock split work?
NovaBay Pharmaceuticals shares reverse split on the morning of Monday, December 21st 2015. The 1-25 reverse split was announced on Friday, December 11th 2015. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 18th 2015. An investor that had 100 shares of NovaBay Pharmaceuticals stock prior to the reverse split would have 4 shares after the split.
How were NovaBay Pharmaceuticals' earnings last quarter?
NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) announced its quarterly earnings results on Tuesday, November, 14th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.07) by $0.09. The biopharmaceutical company had revenue of $4.09 million for the quarter, compared to analyst estimates of $4.69 million. NovaBay Pharmaceuticals had a negative return on equity of 184.30% and a negative net margin of 42.16%. View NovaBay Pharmaceuticals' Earnings History.
Where is NovaBay Pharmaceuticals' stock going? Where will NovaBay Pharmaceuticals' stock price be in 2017?
5 Wall Street analysts have issued 1-year price targets for NovaBay Pharmaceuticals' stock. Their forecasts range from $5.00 to $8.00. On average, they anticipate NovaBay Pharmaceuticals' stock price to reach $6.25 in the next twelve months. View Analyst Ratings for NovaBay Pharmaceuticals.
What are Wall Street analysts saying about NovaBay Pharmaceuticals stock?
Here are some recent quotes from research analysts about NovaBay Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of antimicrobial compounds, which it has named Aganocide compounds, which are based upon small molecules that are generated by white blood cells that defend the body against invading pathogens. NovaBay believes that Aganocide compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of bacterial and viral infections, including Methicillin-Resistant Staphylococcus aureus. " (10/12/2017)
- 2. Maxim Group analysts commented, "NovaBay reported 4Q16 revenue of 4M, inline with preannouncement back in January. Operating expenses were $6.1M up from the prior quarter's $5.5M. This translated into a net loss of $1.6M or $(0.11) per share. Novabay ended the quarter with $9.5M in cash or about $7M (est.) in cash today... We have adjusted our model to reflect the revenue guidance. We conclude that without a revenue breakout, (driven by additional capital), our model suggests a target valuation in the current range. As such, we maintain our Hold rating." (3/24/2017)
Who are some of NovaBay Pharmaceuticals' key competitors?
Some companies that are related to NovaBay Pharmaceuticals include Silence Therapeutics plc (SLN), Bioventix PLC (BVXP), Compugen (CGEN), Asterias Biotherapeutics (AST), Advaxis (ADXS), Oramed Pharmaceuticals (ORMP), CTI BioPharma Corp. (CTIC), ArQule (ARQL), aTyr Pharma (LIFE), Eiger BioPharmaceuticals (EIGR), Matinas BioPharma Holdings (MTNB), BioLineRx (BLRX), Infinity Pharmaceuticals (INFI), Sunesis Pharmaceuticals (SNSS), Galectin Therapeutics (GALT), Regulus Therapeutics (RGLS), Senomyx (SNMX) and Novelion Therapeutics (NVLN).
Who are NovaBay Pharmaceuticals' key executives?
NovaBay Pharmaceuticals' management team includes the folowing people:
- Mark M. Sieczkarek, Interim Chairman of the Board, President, Chief Executive Officer
- John McGovern, Chief Financial Officer, Treasurer
- Justin M. Hall Esq., Senior Vice President, General Counsel
- Xinzhou Li, Director
- Xiaoyan Liu, Director
- Yonghao Ma Ph.D., Director
- , Bio & Compensation -
- Mijia Wu, Director
- Todd E. Zavodnick, Director
How do I buy NovaBay Pharmaceuticals stock?
Shares of NovaBay Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NovaBay Pharmaceuticals' stock price today?
One share of NovaBay Pharmaceuticals stock can currently be purchased for approximately $4.35.
How big of a company is NovaBay Pharmaceuticals?
NovaBay Pharmaceuticals has a market capitalization of $72.27 million.
How can I contact NovaBay Pharmaceuticals?
NovaBay Pharmaceuticals' mailing address is 2000 Powell St Ste 1150, EMERYVILLE, CA 94608-1804, United States. The biopharmaceutical company can be reached via phone at +1-510-8998800.
MarketBeat Community Rating for NovaBay Pharmaceuticals (NBY)MarketBeat's community ratings are surveys of what our community members think about NovaBay Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 1 Hold Rating, 4 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 2.80)|
|Consensus Price Target: ||$6.25|
Consensus Price Target History for NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)
Analysts' Ratings History for NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)
(Data available from 11/24/2015 forward)
|11/15/2017||Laidlaw||Lower Price Target||Buy -> Buy||$10.00 -> $8.00|
|11/15/2017||HC Wainwright||Set Price Target||Buy||$6.00|
|10/23/2017||Roth Capital||Set Price Target||Buy||$5.00|
|8/11/2017||Maxim Group||Reiterated Rating||Hold|
|2/6/2017||Rodman & Renshaw||Initiated Coverage||Buy||$6.00|
Earnings History and Estimates Chart for NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)
Earnings History by Quarter for NovaBay Pharmaceuticals (NYSEAMERICAN NBY)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/14/2017||Q3||($0.07)||($0.16)||$4.69 million||$4.09 million||View||N/A|
|8/10/2017||Q2 2017||($0.12)||($0.11)||$4.57 million||$4.12 million||View||N/A|
|11/10/2016||Q316||($0.16)||($0.34)||$3.02 million||$3.40 million||View||N/A|
|8/11/2016||Q216||($0.30)||($0.36)||$1.76 million||$2.70 million||View||Listen|
|5/12/2016||Q116||($0.68)||($1.24)||$1.84 million||$1.70 million||View||Listen|
|3/3/2016||Q415||($1.36)||($1.26)||$1.43 million||$1.60 million||View||N/A|
|11/19/2015||Q315||($0.07)||($0.07)||$1.06 million||$1.20 million||View||Listen|
|3/14/2013||Q4 2012||($0.09)||($0.08)||$1.50 million||View||N/A|
Earnings Estimates for NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for NovaBay Pharmaceuticals (NYSEAMERICAN NBY)
Insider Trades by Quarter for NovaBay Pharmaceuticals (NYSEAMERICAN NBY)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/20/2015||Ramin Najafi||CEO||Buy||12,000||$0.47||$5,640.00|| |
|3/3/2015||Pharma (Singapore) Pte Pioneer||Major Shareholder||Buy||2,590,000||$0.60||$1,554,000.00|| |
|3/3/2015||Ramin Najafi||Chairman||Buy||166,666||$0.60||$99,999.60|| |
|12/12/2014||Ramin Najafi||Chairman||Buy||50,000||$0.65||$32,500.00|| |
|12/12/2014||Thomas J Paulson||CFO||Buy||10,000||$0.68||$6,800.00|| |
|12/11/2014||Ramin Najafi||Chairman||Buy||20,000||$0.60||$12,000.00|| |
|12/9/2014||Thomas J Paulson||CFO||Buy||10,000||$0.67||$6,700.00|| |
|12/5/2014||Ramin Najafi||Chairman||Buy||25,000||$0.65||$16,250.00|| |
|12/2/2014||Ramin Najafi||Chairman||Buy||18,000||$0.71||$12,780.00|| |
|12/2/2014||Tony D.S. Wicks||Director||Sell||20,000||$0.70||$14,000.00|| |
|6/4/2014||Mark M Sieczkarek||Director||Buy||4,800||$0.89||$4,272.00|| |
|5/19/2014||Mark M Sieczkarek||Director||Buy||25,000||$0.88||$22,000.00|| |
|5/13/2014||Pioneer Pharma Holdings China||Major Shareholder||Buy||65,065||$0.99||$64,414.35|| |
|5/12/2014||Pioneer Pharma Holdings China||Major Shareholder||Buy||116,107||$0.99||$114,945.93|| |
|5/9/2014||Pioneer Pharma Holdings China||Major Shareholder||Buy||318,828||$0.99||$315,639.72|| |
|12/2/2013||Pioneer Pharma Holdings China||Major Shareholder||Buy||5,000,000||$1.14||$5,700,000.00|| |
|12/11/2012||Xinzhou Li||Insider||Buy||120,000||$1.20||$144,000.00|| |
|12/6/2012||Ramin Najafi||Chairman||Buy||20,000||$1.24||$24,800.00|| |
|12/6/2012||Thomas J Paulson||CFO||Buy||10,000||$1.24||$12,400.00|| |
|10/31/2012||Area Pioneer Pharma Co. Naqu||Major Shareholder||Buy||1,200,000||$1.25||$1,500,000.00|| |
|9/13/2012||Xinzhou Li||Major Shareholder||Buy||800,000||$1.25||$1,000,000.00|| |
Latest Headlines for NovaBay Pharmaceuticals (NYSEAMERICAN NBY)
NovaBay Pharmaceuticals (NYSEAMERICAN NBY) Chart for Friday, November, 24, 2017